Heron Therapeutics Inc Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF Transcript

Dec 09, 2021 / 01:30PM GMT
Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics conference call. As a reminder, this conference is being recorded.

Now I would like to turn the call over to David Szekeres, Executive Vice President, Chief Operating Officer. Please proceed.

David L. Szekeres - Heron Therapeutics, Inc. - Executive VP & COO

Thank you, Jay. Good morning, everyone, and thank you for joining us today to discuss the label expansion for ZYNRELEF. With me today from Heron are Barry Quart, Chief Executive Officer and Chairman; and John Poyhonen, President and Chief Commercial Officer. For those of you participating via conference call, the slides are made available via webcast and can also be accessed by going to the Investor Relations page of our website following the conclusion of today's call.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Heron's future expectations, plans, prospects, corporate strategy and performance, which constitute forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot